Recordati (RECI)

Milan
Currency in EUR
55.95
-3.95(-6.59%)
Real-time Data
RECI Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
Unusual trading volume
Fair Value
Day's Range
55.4057.10
52 wk Range
47.2860.95
Key Statistics
Edit
Prev. Close
59.9
Open
55.4
Day's Range
55.4-57.1
52 wk Range
47.28-60.95
Volume
1.51M
Average Volume (3m)
283.69K
1-Year Change
16.9%
Book Value / Share
9.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RECI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
58.19
Upside
+4.00%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Recordati Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea. It also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma; and FOTIVDA, an oral inhibitor first-line treatment of renal cell carcinoma. In addition, the company offers SYLVANT for the treatment of idiopathic multicentric castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment electrolyte supersaturated of oral mucositis due to chemo and radiation therapy. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Rossini S.à R.L.

Employees
4455
Market
Italy

Compare RECI to Peers and Sector

Metrics to compare
RECI
Peers
Sector
Relationship
P/E Ratio
29.4x18.2x−0.7x
PEG Ratio
-0.060.00
Price/Book
6.5x2.2x2.6x
Price / LTM Sales
5.2x2.3x3.1x
Upside (Analyst Target)
−4.7%17.4%49.4%
Fair Value Upside
Unlock14.1%8.9%Unlock

Analyst Ratings

4 Buy
4 Hold
2 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 58.19
(+4.00% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.05
Dividend Yield
2.05%
Industry Median 2.23%
Annualised payout
1.23
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 12, 2025
EPS / Forecast
-- / --
Revenue / Forecast
598.80M / 543.44M
EPS Revisions
Last 90 days

FAQ

What Is the Recordati (RECI) Stock Price Today?

The Recordati stock price today is 55.95.

What Stock Exchange Does Recordati Trade On?

Recordati is listed and trades on the Milan stock exchange.

What Is the Stock Symbol for Recordati?

The stock symbol for Recordati is "RECI."

Does Recordati Pay Dividends? What’s The Current Dividend Yield?

The Recordati dividend yield is 2.06%.

What Is the Recordati Market Cap?

As of today, Recordati market cap is 11.43B.

What is Recordati Earnings Per Share?

The Recordati EPS is 2.05.

What Is the Next Recordati Earnings Date?

Recordati will release its next earnings report on 07 May 2025.

From a Technical Analysis Perspective, Is RECI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.